{"id":"NCT01828112","sponsor":"Novartis Pharmaceuticals","briefTitle":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","officialTitle":"A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-28","primaryCompletion":"2016-01-26","completion":"2023-11-10","firstPosted":"2013-04-10","resultsPosted":"2017-07-27","lastUpdate":"2025-02-07"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Ceritinib","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"Ceritinib","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib. Patients in the chemotherapy arm were given the option to switch to LDK378 after confirmed progressive disease (PD), while also had the choice to continue with pemetrexed treatment.","primaryOutcome":{"measure":"Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC)","timeFrame":"From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months","effectByArm":[{"arm":"Ceritinib","deltaMin":5.4,"sd":null},{"arm":"Chemotherapy","deltaMin":1.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":97,"countries":["United States","Belgium","Canada","France","Germany","Hong Kong","Ireland","Israel","Italy","Japan","Lebanon","Netherlands","Portugal","Russia","Singapore","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["29474558","28602779"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":["Diarrhoea","Nausea","Vomiting","Decreased appetite","Alanine aminotransferase increased"]}}